A Review on FDA Approval of Lymphoma Drug Ukoniq (Umbralisib) And Its Withdrwal Due to Safety Concerns . Journal of Pharmaceutical Negative Results, [S. l.], v. 13, n. 4, p. 1465–1474, 2022. DOI: 10.47750/pnr.2022.13.04.206. Disponível em: https://www.pnrjournal.com/index.php/home/article/view/4551.. Acesso em: 23 jun. 2026.